Wan-Fai Ng
University of Newcastle upon Tyne
Walter Maetzler
Universitätsklinikum Schleswig-Holstein
Ioannis Pandis
Janssen Pharmaceutica NV
Patricio O’Donnell
Takeda Development Centre Europe Ltd
David Wenn
iXscient Ltd
Mike Jackson
iXscient Ltd
Sofia Jacob
Janssen Pharmaceutica NV
Walter Maetzler
Universitätsklinikum Schleswig-Holstein
Armella Escher
Takeda Development Centre Europe Ltd
Manisha Madhoo
Takeda Development Centre Europe Ltd
Jan Smeddinck
University of Newcastle upon Tyne
Ioannis Pandis
Janssen Pharmaceutica NV
Teemu Ahmaniemi
Teknologian tutkimuskeskus VTT Oy
Meenakshi Chatterjee
Janssen Pharmaceutica NV
Andrew McCarthy
Eli Lilly & Co. Ltd
Yi-Ke Guo
Imperial College of Science Technology and Medicine
Kai Sun
Imperial College of Science Technology and Medicine
Ioannis Pandis
Janssen Pharmaceutica NV
Sabine Kläger
ECRIN European Clinical Research Infrastructure Network
Nadir Ammour
Sanofi Aventis Recherche et Développement
Jérôme Kalifa
Let it Care SAS
Stefan Avey
Janssen Pharmaceutica NV
Evert-Ben van Veen
Stichting MLC Foundation
Muriel Mignolet
Takeda Development Centre Europe Ltd
Manisha Madhoo
Takeda Development Centre Europe Ltd
Veli Stroetmann
empirica Gesellschaft für Kommunikations und Technologieforschung Mbh
David Nobbs
F. Hoffmann-La Roche AG
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.